The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: A meta-analysis and literature review

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zhang, Lu ^a   Han, Jianjun ^a   Wu, Huiyong ^a   Liang, Xiaohong ^b   Zhang, Jianxin ^a   Li, Jian ^a   Xie, Li ^a   Xie, Yinfa ^a   Sheng, Xiugui ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; TUMOR MARKER; HMGB1 PROTEIN, HUMAN; TUMOR PROTEIN;

CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DOWN REGULATION; GENE OVEREXPRESSION; HMGB1 GENE; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; UPREGULATION; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; LIVER TUMOR; MEDLINE; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; SURVIVAL RATE;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; LIVER NEOPLASMS; MEDLINE; NEOPLASM PROTEINS; NEOPLASM STAGING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84908668288     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110626     Document Type: Review

References (74)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
3. Bosch FX, Ribes J, Diaz M, Clerics R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16.
4. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763.
5. Forner A, Bruix J (2008) Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. Hepatology 47: 5-7.
6. Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23: 2892-2899.
7. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417-4-22.
8. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, et al. (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34: 570-575.
9. Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, et al. (2002) Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 20: 305-309.
10. Khien W, Mao HV, Chinh TT, Ha PT, Bang MH, et al. (2001) Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 16: 105-111.
11. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, et al. (2010) AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 45: 1272-1282.
12. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, et al. (2006) Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101: 2038-2043.
13. Tian L, Wang Y, Xu D, GuiJ,Jia X, et al. (2011) Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer 129: 1923-1931.
14. Qi J, Wang J, Katayama H, Sen S, Liu SM (2013) Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 60: 135-142.
15. Pinato DJ, Pirisi M, Maslen L, Sharma R (2014) Tissue biomarkers of prognostic significance in hepatocellular carcinoma. Adv Anat Pathol 21: 270-284.
16. Goodwin GH, Johns EW (1973) Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids. Eur J Biochem 40: 215-219.
17. Goodwin GH SC, Johns EW (1973) A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 38: 14-19.
18. Weir HM, Kraulis PJ, Hill CS, Raine AR, Laue ED, et al. (1993) Structure of the HMG box motif in the B-domain of HMG1. EMBO J 12: 1311-1319.
19. Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG (1993) Solution structure of a DNA-binding domain from HMGl. Nucleic Acids Res
20. Liu Y, Prasad R, Wilson SH (2010) HMGB1: roles in base excision repair and related function. Biochim Biophys Acta 1799: 119-130.
21. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
22. Tang D, Kang R, Zeh HJ, 3rd, Lotze MT (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140.
23. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, et al. (2006) Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic C-IAP2 protein in human colon carcinomas. Gut 55: 234-242.
24. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, et al. (2003) Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63: 2188-2193.
25. Hao Q, Du XQ, Fu X, Tian J (2008) [Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma]. Zhonghua Zhong Liu Za Zhi 30: 292-295.
26. Poser I, Golob M, Buettner R, Bosserhoff AK (2003) Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23: 2991-2998.
27. Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, et al. (2013) Serum hmgb1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 13: 205.
28. Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, et al. (2013) Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 132: 2349-2358.
29. Chiharu Tabata ES, Rie Tabata, Shingo Kanemura, Koji Mikami, Yoshitaka Nogi, et al. (2013) Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 13: 1-6.
30. Jiang W, Wang Z, Li X, Fan X, Duan Y (2012) High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res 18: 293-298.
31. Liu F, Zhang Y, Peng Z, Gao H, Xu L, et al. (2012) High expression of high mobility group box 1 (hmgbl) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transi Med 10: 135.
32. Ueno S HK, Sakoda M, lino S, Kurahara H MK, Ando K, et al. (2011) Significance of High Mobility Group Box-1 (HMGB1) Expression in Hepatocellular Carcinoma. Med J Kago Shima Univ 62: 27-35.
33. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, et al. (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundandy expressed in human breast carcinoma. FASEB J 17: 1295-1297.
34. Thomas JO, Travers AA (2001) HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci 26: 167-174.
35. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, et al. (2008) S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 83: 1484-1492.
36. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, et al. (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179: 33-40.
37. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, et al. (2007) High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 30: 596-606.
38. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGBl by necrotic cells triggers inflammation. Nature 418: 191-195.
39. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGBl and RAGE. Nat Immunol 8: 487-496.
40. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
41. Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, et al. (2007) Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 27: 449-457.
42. Wu D, Ding Y, Wang S, Zhang Q, Liu L (2008) Increased expression of high mobility group box 1 (HMGBl) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 216: 167-175.
43. Liu Y, Xie C, Zhang X, Huang D, Zhou X, et al. (2010) Elevated expression of HMGBl in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46: 3007-3015.
44. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGBl): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342.
45. Naglova H, Bucova M (2012) HMGBl and its physiological and pathological roles. Bratisl Lek Listy 113: 163-171.
46. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, et al. (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205: 275-285.
47. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, et al. (2010) TLR 4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29: 2242-2252.
48. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, et al. (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170.
49. Sasahira T, Akama Y, Fujii K, Kuniyasu H (2005) Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446: 4-11 -4-15.
50. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P (2005) HMGBl: guiding immunity from within. Trends Immunol 26: 381-387.
51. Evans A, Lennard TW, Davies BR (2004) High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol 88: 86-99.
52. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, et al. (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360.
53. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y (2004) Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 51: 928-930.
54. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62: 4805-4811.
55. Dong YD, Cui L, Peng CH, Cheng DF, Han BS, et al. (2013) Expression and clinical significance of HMGBl in human liver cancer: Knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol Rep 29: 87-94.
56. Xiao J, Ding Y, Huang J, Li Q, Liu Y, et al. (2014) The association of HMGBl gene with the prognosis of HCC. PLoS One 9: e89097.
57. Wang Y (2013) Expression, Subcellular Location and Prognostic Relevance of High Mobility Group Box l(HMGBl) in Hepatocellular Carcinoma. University of Science and Technology Graduation Thesis 2013: 11-14. Available: cdmd.cnki.com.cn/Article/CDMD-10487-1013273569.htm
58. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, et al. (2012) Cancer cell secretion of the DAMP protein HMGBl supports progression in malignant mesothelioma. Cancer Res 72: 3290-3301.
59. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, et al. (2014) The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 33: 567-577.
60. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, et al. (2012) High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 55: 1863-1875.
61. Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, et al. (2011) Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erkl/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis 32: 1167-1175.
62. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, et al. (2013) Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 32: 363-374.
63. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, et al. (2007) The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 450: 287-295.
64. Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, et al. (2009) Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76: 155-162.
65. Liu Z, Falo LD, Jr., You Z (2011) Knockdown of HMGBl in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol 187: 118-125.
66. He Y, Zha J, Wang Y, Liu W, Yang X, et al. (2013) Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res 73: 629-639.
67. Liu HB, Fan XG, Huang JJ, Li N, Peng JP, et al. (2007) [Serum level of HMGB1 in patients with hepatitis B and its clinical significance]. Zhonghua Gan Zang Bing Za Zhi 15: 812-815.
68. Jung JH, Park JH, Jee MH, Keum SJ, Cho MS, et al. (2011) Hepatitis C virus infection is blocked by HMGBl released from virus-infected cells. J Virol 85: 9359-9368.
69. Zhou RR, Zhao SS, Zou MX, Zhang P, Zhang BX, et al. (2011) HMGBl cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol 11: 21.
70. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, et al. (2008) Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 40: 446-452.
71. Han F WT, Chen G (2014) Changes of high mobility group box 1 expression in hepatocellular carcinoma tissues. Journal of Medical Postgraduates 4.
72. Gou H SL, Han L (2013) Detection and clinical significance of high mobility group box protein 1 in liver cancer. Journal of Preventive Medicine 40.
73. Wang T HF, Liang J, Wang F, Chen G (2013) Increased HMGBl expression in primary hepatic carcinoma and its mechanism Chinese Journal of Laboratory Diagnosis 17: 1783-1785.
74. Feng H (2011) The Expression and Clinical Significance of High Mobility Group Protein B 1 in Hepatocellular Carcinoma Chongqing Medical University Graduation Thesis: 11 -17. Available: CDMD-10631-1011173410.htm